These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 32378820)

  • 1. The Effects of Adalimumab in Behçet Disease Patients on Clinical Manifestations and on Pro-Inflammatory Cytokines Milieu: Long-Term Follow-Up.
    Braun-Moscovici Y; Tavor Y; Markovits D; Toledano K; Rozin A; Nahir MA; Balbir-Gurman A
    Isr Med Assoc J; 2020 May; 22(5):289-293. PubMed ID: 32378820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adalimumab for the treatment of Japanese patients with intestinal Behçet's disease.
    Tanida S; Inoue N; Kobayashi K; Naganuma M; Hirai F; Iizuka B; Watanabe K; Mitsuyama K; Inoue T; Ishigatsubo Y; Suzuki Y; Nagahori M; Motoya S; Nakamura S; Arora V; Robinson AM; Thakkar RB; Hibi T
    Clin Gastroenterol Hepatol; 2015 May; 13(5):940-8.e3. PubMed ID: 25245624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adalimumab for treatment of severe Behçet's uveitis: a retrospective long-term follow-up study.
    Interlandi E; Leccese P; Olivieri I; Latanza L
    Clin Exp Rheumatol; 2014; 32(4 Suppl 84):S58-62. PubMed ID: 25005224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adalimumab provides long-lasting clinical improvement in refractory mucocutaneous Behçet's disease without formation of antidrug antibodies.
    Verboom DM; van der Houwen TB; Kappen JH; van Daele PLA; Dik WA; Schreurs MWJ; van Hagen PM; van Laar JAM
    Clin Exp Rheumatol; 2019; 37 Suppl 121(6):43-47. PubMed ID: 30873952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neutrophilic eccrine hidradenitis as a clue to the diagnosis of Behçet's disease: Case report with excellent response to adalimumab.
    Baeza-Hernández G; Rubio-Aguilera RF; Horcajada-Reales C; Khedaoui R; Romero-Maté A
    Australas J Dermatol; 2024 May; 65(3):e66-e68. PubMed ID: 38212933
    [No Abstract]   [Full Text] [Related]  

  • 6. Marked improvement in gastric involvement in Behçet's disease with adalimumab treatment.
    Sonoda A; Ogawa R; Mizukami K; Fukuda K; Shuto M; Okamoto K; Matsunari O; Okimoto T; Murakami K
    Turk J Gastroenterol; 2017 Sep; 28(5):405-407. PubMed ID: 28797990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term data on efficacy and safety of adalimumab in Behçet's disease.
    van der Houwen TB; Humer B; Missotten TO; Thiadens AAHJ; van Hagen PM; van Laar JAM
    Clin Immunol; 2023 Feb; 247():109242. PubMed ID: 36717068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful Treatment with Adalimumab for Intestinal Behcet's Disease during Pregnancy.
    Fujikawa K; Endo Y; Mizokami A; Takahashi K; Tabuchi M; Ohba K; Nakamura H; Kawakami A
    Intern Med; 2016; 55(10):1375-8. PubMed ID: 27181551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cumulative retention rate of adalimumab in patients with Behçet's disease-related uveitis: a four-year follow-up study.
    Fabiani C; Sota J; Vitale A; Rigante D; Emmi G; Vannozzi L; Bacherini D; Lopalco G; Guerriero S; Gentileschi S; Capozzoli M; Franceschini R; Frediani B; Galeazzi M; Iannone F; Tosi GM; Cantarini L
    Br J Ophthalmol; 2018 May; 102(5):637-641. PubMed ID: 28844047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful treatment with adalimumab in a familial case of gastrointestinal Behcet's disease.
    De Cassan C; De Vroey B; Dussault C; Hachulla E; Buche S; Colombel JF
    J Crohns Colitis; 2011 Aug; 5(4):364-8. PubMed ID: 21683309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of apremilast for Behçet's syndrome: a real-life single-centre Italian experience.
    De Luca G; Cariddi A; Campochiaro C; Vanni D; Boffini N; Tomelleri A; Cavalli G; Dagna L
    Rheumatology (Oxford); 2020 Jan; 59(1):171-175. PubMed ID: 31280296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world efficacy of adalimumab and infliximab for refractory intestinal Behçet's disease.
    Sugimura N; Mizoshita T; Sugiyama T; Togawa S; Miyaki T; Suzuki T; Tanida S; Kataoka H; Sasaki M
    Dig Liver Dis; 2019 Jul; 51(7):967-971. PubMed ID: 30872086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infliximab treatment for ocular and extraocular manifestations of Behçet's disease.
    Accorinti M; Pirraglia MP; Paroli MP; Priori R; Conti F; Pivetti-Pezzi P
    Jpn J Ophthalmol; 2007; 51(3):191-6. PubMed ID: 17554481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of adalimumab in patients with Behçet's disease unsuccessfully treated with infliximab.
    Olivieri I; Leccese P; D'Angelo S; Padula A; Nigro A; Palazzi C; Coniglio G; Latanza L
    Clin Exp Rheumatol; 2011; 29(4 Suppl 67):S54-7. PubMed ID: 21968237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of the anti-IL 17 secukinumab in refractory Behçet's syndrome: A preliminary study.
    Di Scala G; Bettiol A; Cojan RD; Finocchi M; Silvestri E; Emmi G
    J Autoimmun; 2019 Feb; 97():108-113. PubMed ID: 30213443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Articular manifestations of aphthosis (Behcet's syndrome)].
    Bisson M; Amor B; Kahan A; Delbarre F
    Sem Hop; 1971 Jul; 47(31):2023-33. PubMed ID: 4327287
    [No Abstract]   [Full Text] [Related]  

  • 17. Safety and Efficacy of Adalimumab in Patients with Noninfectious Uveitis in an Ongoing Open-Label Study: VISUAL III.
    Suhler EB; Adán A; Brézin AP; Fortin E; Goto H; Jaffe GJ; Kaburaki T; Kramer M; Lim LL; Muccioli C; Nguyen QD; Van Calster J; Cimino L; Kron M; Song AP; Liu J; Pathai S; Camez A; Schlaen A; van Velthoven MEJ; Vitale AT; Zierhut M; Tari S; Dick AD
    Ophthalmology; 2018 Jul; 125(7):1075-1087. PubMed ID: 29429764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-interleukin 6 receptor tocilizumab in refractory uveitis associated with Behçet's disease: multicentre retrospective study.
    Atienza-Mateo B; Calvo-Río V; Beltrán E; Martínez-Costa L; Valls-Pascual E; Hernández-Garfella M; Atanes A; Cordero-Coma M; Miquel Nolla J; Carrasco-Cubero C; Loricera J; González-Vela MC; Vegas-Revenga N; Fernández-Díaz C; Demetrio-Pablo R; Domínguez-Casas LC; Luis Martín-Varillas J; Palmou-Fontana N; Hernández JL; González-Gay MÁ; Blanco R
    Rheumatology (Oxford); 2018 May; 57(5):856-864. PubMed ID: 29471416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment of Behçet's disease with adalimumab].
    Callejas-Rubio JL; Sánchez-Cano D; Ríos-Férnandez R; Ortego-Centeno N
    Med Clin (Barc); 2008 Oct; 131(11):438-9. PubMed ID: 18928730
    [No Abstract]   [Full Text] [Related]  

  • 20. Efficacy of switching to adalimumab in a patient with refractory uveitis of Behçet's disease to infliximab.
    Leccese P; Latanza L; D'Angelo S; Padula A; Olivieri I
    Clin Exp Rheumatol; 2011; 29(4 Suppl 67):S93. PubMed ID: 21813069
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.